You are here

BMS Halts Study of Hepatitis C Drug

In a brief statement, BMS said that "the cause of the safety issue and any potential relationship to study drug are unknown at this time."

The suspension is considered a major setback for the company.

The Journal noted that BMS, Gilead Sciences Inc., Abbott Laboratories, and other companies are racing to bring an oral hepatitis C drug regimen to market to replace the current standard treatment, injectable interferon, which can be difficult for patients to tolerate.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug